IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 159 filers reported holding IMPAX LABORATORIES INC in Q3 2013. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $4,104,000 | -49.1% | 254,905 | -60.0% | 0.02% | -44.4% |
| Q1 2017 | $8,066,000 | -42.9% | 637,649 | -40.2% | 0.03% | -50.0% |
| Q4 2016 | $14,122,000 | +1656.5% | 1,065,779 | +3042.4% | 0.05% | +1700.0% |
| Q3 2016 | $804,000 | -48.0% | 33,916 | -36.8% | 0.00% | -57.1% |
| Q2 2016 | $1,546,000 | -37.9% | 53,657 | -31.0% | 0.01% | -41.7% |
| Q1 2016 | $2,489,000 | -75.8% | 77,724 | -67.6% | 0.01% | -75.5% |
| Q4 2015 | $10,265,000 | +962.6% | 240,070 | +775.2% | 0.05% | +880.0% |
| Q3 2015 | $966,000 | -91.4% | 27,429 | -88.7% | 0.01% | -90.4% |
| Q2 2015 | $11,177,000 | +3339.1% | 243,410 | +3408.9% | 0.05% | +2500.0% |
| Q1 2015 | $325,000 | -43.6% | 6,937 | -63.9% | 0.00% | -33.3% |
| Q2 2014 | $576,000 | -92.6% | 19,216 | -93.5% | 0.00% | -92.9% |
| Q1 2014 | $7,779,000 | +4.8% | 294,421 | -0.3% | 0.04% | +2.4% |
| Q4 2013 | $7,425,000 | +108.5% | 295,341 | +70.0% | 0.04% | +78.3% |
| Q3 2013 | $3,562,000 | – | 173,690 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 5,415,600 | $162,414,000 | 1.91% |
| Broadfin Capital, LLC | 1,217,858 | $36,524,000 | 1.80% |
| NEW AMSTERDAM PARTNERS LLC/NY | 695,100 | $20,846,000 | 1.36% |
| Healthcare Value Capital, LLC | 50,000 | $1,500,000 | 1.26% |
| Iguana Healthcare Management, LLC | 75,000 | $2,249,000 | 1.05% |
| Matarin Capital Management, LLC | 78,292 | $2,347,977,000 | 1.04% |
| Independence Capital Asset Partners, LLC | 253,089 | $7,590,000 | 1.04% |
| Tekla Capital Management LLC | 344,683 | $10,337,000 | 0.95% |
| Penn Capital Management Company, LLC | 794,641 | $23,831,000 | 0.92% |
| Leonard Capital Management, Inc. | 87,661 | $2,629,000 | 0.89% |